Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) scored a win in a late-stage trial for the treatment of rheumatoid arthritis (RA). The company, in conjunction with Sanofi, announced that a Phase 3 monotherapy study met its…
Corvus Pharmaceuticals expects to price more than 4 million shares in the range of $15 to $17 apiece in an initial public offering valued up to nearly $92 million.
The February 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest decreased.
The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Valeant Pharmaceuticals International CEO Michael Pearson needs to leave the company he leads, as its problems continue to grow rapidly.
Amarin made some headway in Wednesday's regular trading session following a settlement with the U.S. Food and Drug Administration.
With biotechs still way out of favor, investors need to be cautious, as often these companies are dependent on binary data. These three could have positive upcoming data presented.
InVivo Therapeutics saw its shares surge by over 25% Monday on a pivotal announcement from its Inspire study.
Celldex Therapeutics Inc. (NASDAQ: CLDX) got burned in Monday’s regular trading session and ultimately saw its shares fall by over 50%. The reasoning behind this? The independent Data Safety and Monitoring Board (DSMB) has…
In Monday's trading session, it seems that investors are finally coming around and trusting Valeant Pharmaceuticals.
Over the past week, Halozyme Therapeutics and a couple of other biotech companies made impressive runs.
Canaccord Genuity has downgraded Valeant Pharmaceuticals due to the growing uncertainty surrounding its multitude of investigations, both internal and external.
Medtronic released its fiscal third-quarter earnings report before the markets opened on Tuesday and shares tumbled.
Medtronic is scheduled to report its fiscal third-quarter financial results before the markets open on Tuesday.
Novavax reported disappointing fourth-quarter financial results before the markets opened on Monday.
